Loss of major histocompatibility complex Class II gene expression predicts poor survival in diffuse large B celllymphoma
Rimsza, L.M.; Leblanc, M.; Braziel, R.; Jaramillo, M.; Miller, T.P.; Staudt, L.; Grogan, T.M.; Fisher, R.
Modern Pathology 16(1): 250A
2003
ISSN/ISBN: 0893-3952 Accession: 035240672
PDF emailed within 1 workday: $29.90
Related References
Miller, T.P.; Leblanc, M.; Grogan, T.M.; Braziel, R.M.; Staudt, L.M.; Fisher, R.I. 2002: Major Histocompatibility Complex Class II Antigen HLA-DR Gene Expression Levels in Diffuse Large B-Cell Lymphoma Correlate with Survival Blood 100(11): Abstract No. 1341Roberts, R.A.; Wright, G.; Rosenwald, A.R.; Jaramillo, M.A.; Grogan, T.M.; Miller, T.P.; Frutiger, Y.; Chan, W.C.; Gascoyne, R.D.; Ott, G.; Muller-Hermelink, H.Konrad.; Staudt, L.M.; Rimsza, L.M. 2006: Loss of major histocompatibility class II gene and protein expression in primary mediastinal large B-cell lymphoma is highly coordinated and related to poor patient survival Blood 108(1): 311-318
Wilkinson, S.T.; Fernandez, D.R.; Murphy, S.P.; Braziel, R.M.; Campo, E.; Chan, W.C.; Delabie, J.; Gascoyne, R.D.; Staudt, L.M.; Jaffe, E.S.; Rosenwald, A.; Rimsza, L.M. 2009: Decreased major histocompatibility complex class Ii expression in diffuse large B-cell lymphoma does not correlate with CpG methylation of class Ii transactivator promoters IIi and IV Leukemia and Lymphoma 50(11): 1875-1878
Rimsza, L.M.; Chan, W.C.; Gascoyne, R.D.; Campo, E.; Jaffe, E.S.; Staudt, L.M.; Delabie, J.; Rosenwald, A.; Murphy, S.P. 2009: CIITA or RFX coding region loss of function mutations occur rarely in diffuse large B-cell lymphoma cases and cell lines with low levels of major histocompatibility complex class Ii expression Haematologica 94(4): 596-598
Medeiros, L.J.; Gelb, A.B.; Wolfson, K.; Doggett, R.; McGregor, B.; Cox, R.S.; Horning, S.J.; Warnke, R.A. 1993: Major histocompatibility complex class i and class Ii antigen expression in diffuse large cell and large cell immunoblastic lymphomas. Absence of a correlation between antigen expression and clinical outcome American Journal of Pathology 143(4): 1086-1097
Rimsza, L.; Roberts, R.; Campo, E.; Grogan, T.; Bea, S.; Salaverria, I.; Zettl, A.; Fisher, R.; Unger, J.; Leblanc, M.; Staudt, L.; Gascoyne, R.; Chan, W.; Weisenburger, D.; Greiner, T.; Jaffe, E.; Braziel, R.; Mueller Hermelink, K. 2003: Loss of major histocompatibility class II expression in nodal diffuse large B cell lymphoma is highly coordinated and unlikely related to chromosomal deletions Blood 102(11): 893a
Rimsza, L.M.; Roberts, R.A.; Campo, E.; Grogan, T.M.; Bea, S.; Salaverria, I.; Zettl, A.; Rosenwald, A.; Ott, G.; Muller-Hermelink, H.K.; Delabie, J.; Fisher, R.I.; Unger, J.M.; Leblanc, M.; Staudt, L.M.; Jaffe, E.S.; Gascoyne, R.D.; Chan, W.C.; Weisenburger, D.D.; Greiner, T.; Braziel, R.M.; Miller, T.P. 2006: Loss of major histocompatibility class Ii expression in non-immune-privileged site diffuse large B-cell lymphoma is highly coordinated and not due to chromosomal deletions Blood 107(3): 1101-1107
Rybski, J.A.; Spier, C.M.; Miller, T.P.; Mcgee, D.L.; Grogan, T.M. 1991: Prediction of outcome in diffuse large cell lymphoma by the major histocompatibility complex class i and class ii Laboratory Investigation 64(1): 83A
Rybski, J.A.; Spier, C.M.; Miller, T.P.; Lippman, S.M.; McGee, D.L.; Grogan, T.M. 1991: Prediction of Outcome in Diffuse Large Cell Lymphoma by the Major Histocompatibility Complex Class Ii (HLA-DR, DP, DQ) and Class i (HLA-A, B, C) Phenotype Leukemia and Lymphoma 6(1): 31-38
Rimsza, L.M.; Roberts, R.A.; Miller, T.P.; Unger, J.M.; LeBlanc, M.; Braziel, R.M.; Weisenberger, D.D.; Chan, W.C.; Muller-Hermelink, H.Konrad.; Jaffe, E.S.; Gascoyne, R.D.; Campo, E.; Fuchs, D.A.; Spier, C.M.; Fisher, R.I.; Delabie, J.; Rosenwald, A.; Staudt, L.M.; Grogan, T.M. 2004: Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project Blood 103(11): 4251-4258
Wilkinson, S.T.; Vanpatten, K.A.; Fernandez, D.R.; Brunhoeber, P.; Garsha, K.E.; Glinsmann-Gibson, B.J.; Grogan, T.M.; Teruya-Feldstein, J.; Rimsza, L.M. 2012: Partial plasma cell differentiation as a mechanism of lost major histocompatibility complex class II expression in diffuse large B-cell lymphoma Blood 119(6): 1459-1467
Guo, R.; Zou, P.; Song, Y.-p.; Ma, J.; Lu, H.-z.; Cao, Y.-l.; Tong, Y.-j. 2003: Major histocompatibility complex class Ii transactivator (CIITA) hammer- head ribozyme transfer inhibits major histocompatibility complex class Ii (MHC-II) expression in Jukart cells Zhonghua Er Ke Za Zhi 41(12): 925-928
Feng, X.M.; Chen, X.L.; Liu, N.; Chen, Z.; Zhou, Y.L.; Han, Z.B.; Zhang, L.; Han, Z.C. 2007: Interleukin-27 upregulates major histocompatibility complex class Ii expression in primary human endothelial cells through induction of major histocompatibility complex class Ii transactivator Human Immunology 68(12): 965-972
Yamaguchi, Y.; Goto, M.; Hamaguchi, H.; Hisama, N.; Miyanari, N.; Ichiguchi, O.; Mori, K.; Ogawa, M. 1995: Effects of class i major histocompatibility complex antigens on hepatic allograft survival in rats: distribution of donor cells which express class i major histocompatibility complex antigens in the recipient Transplantation Proceedings 27(1): 540-542
Plaeger-Marshall, S.; Haas, A.; Clement, L.T.; Giorgi, J.V.; Chen, I.S.; Quan, S.G.; Gatti, R.A.; Stiehm, E.R. 1988: Interferon-induced expression of class II major histocompatibility antigens in the major histocompatibility complex (MHC) class II deficiency syndrome Journal of Clinical Immunology 8(4): 285-295
Finn, P.W.; Van, T.T.; Accolla, R.S.; Glimcher, L.H. 1990: Loss of a DNA-protein complex correlates with extinguished major histocompatibility complex class Ii expression in a human B cell Journal of Experimental Medicine 171(6): 2159-2164
Ait-Tahar, K.; Anderson, A.P.; Barnardo, M.; Collins, G.P.; Hatton, C.S.R.; Banham, A.H.; Pulford, K. 2017: Sp17 Protein Expression and Major Histocompatibility Class I and II Epitope Presentation in Diffuse Large B Cell Lymphoma Patients Advances in Hematology 2017: 6527306
Four, M.; Cacheux, V.èr.; Tempier, A.; Platero, D.ès.; Fabbro, M.; Marin, G.ég.; Leventoux, N.; Rigau, V.ér.; Costes-Martineau, V.ér.; Szablewski, V. 2017: PD1 and PDL1 expression in primary central nervous system diffuse large B-cell lymphoma are frequent and expression of PD1 predicts poor survival Hematological Oncology 35(4): 487-496
Brayman, K.L.; Naji, A.; Armstrong, J.; Barker, C.F.; Hickey, W.F. 1986: Cyclosporine and thymic reticuloepithelial cell major histocompatibility complex class i and class ii gene product expression Transplantation Proceedings 18(4): 840-843
McCluskey, J.; Germain, R.N.; Margulies, D.H. 1985: Cell surface expression of an in vitro recombinant class II/class i major histocompatibility complex gene product Cell 40(2): 247-257